137.30USD-4.82%Mkt Cap: 5.50B USDP/E: —Last update: 2026-05-22
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tin…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap5.50B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.61M USD
Revenue/Share—
Last Price137.30 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)111.82
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B7.37
EPS (TTM)-2.54
EPS (Forward)1.29
52W Range
56.1056% of range200.00
52W High200.00 USD
52W Low56.10 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-10.07%
ROA-9.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.99M USD
CapEx (TTM)178.00K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio33.71
Quick Ratio—
Book Value/Sh19.59 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)211.50 USD
Target Range185.00 USD – 266.00 USD
# Analysts8
Ownership
Shares Out.40.09M
Float18.83M
Insiders44.27%
Institutions23.63%
Short Interest
Short Ratio8.8d
Short % Float5.96%
Short % Out.3.09%
Shares Short1.23M
Short (prev mo.)1.04M
Technical
SMA 50159.30 (-13.8%)
SMA 200131.22 (+4.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)126.44K
Avg Vol (10d)148.82K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—